Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
 196 Products   52 Diseases   196 Products   3529 Trials   15381 News 


«12...2324252627282930313233...208209»
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
    Clinical, Retrospective data, Review, Journal:  Efficacy and safety of camrelizumab plus apatinib for solid tumors: a meta-analysis. (Pubmed Central) -  Sep 18, 2025   
    Progression-Free Survival (PFS) rates at the same intervals were 48.4%, 19.8%, and 6.7%. According to the results of this meta-analysis, although the camrelizumab plus apatinib treatment regimen demonstrated certain efficacy in the short term, due to the significant limitations of this study, more high-quality, multicenter, large-sample randomized controlled studies are needed in the future to corroborate our conclusions.
  • ||||||||||  AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
    Journal:  [3-(Trifluoromethyl)-1H-1,2,4-triazol-5-yl]methylamine derivatives: synthesis, ways of modification and use for peptides labeling. (Pubmed Central) -  Sep 17, 2025   
    In particular, 2-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyrazine (23) - a component in the synthesis of Fuzuloparib - was successfully obtained in good yields (56.4%). Finally, we showed that 2-(5-(aminomethyl)-3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl)acetic acid hydrochloride (19) can be incorporated into short peptides using solid phase peptide synthesis, serving as a fluorinated Gly-Gly analogue for peptide 19F NMR studies.
  • ||||||||||  trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
    Trial completion, Trial completion date, Trial primary completion date:  SHR-A1811-I-101: A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors (clinicaltrials.gov) -  Sep 15, 2025   
    P1,  N=396, Completed, 
    PFHO exposure was very low in posterior ocular tissues and negligible in systemic circulation, consistent with the clinical safety profile. Active, not recruiting --> Completed | Trial completion date: Mar 2026 --> Jun 2025 | Trial primary completion date: Dec 2025 --> Jun 2025
  • ||||||||||  AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
    Efficacy of Vunakizumab in Reducing Pain in Ankylosing Spondylitis: A Post-Hoc Analysis of a Phase 2/3 Clinical Trial (Hall F1) -  Sep 15, 2025 - Abstract #ACRConvergence2025ACR_Convergence_2213;    
    Vunakizumab provided statistically significant and clinically meaningful reductions in pain outcomes in patients with active AS. Importantly, patients who switched from placebo to vunakizumab at week 16 experienced rapid pain improvement, supporting vunakizumab as an effective treatment strategy for managing pain in AS.
  • ||||||||||  AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
    Journal:  Fluzoparib disrupts Golgi apparatus to inhibit O-GlcNAcylation and nuclear translocation of ?-catenin to attenuate ovarian cancer invasion and metastasis. (Pubmed Central) -  Sep 13, 2025   
    Mechanistically, FZ disrupts the morphology and function of the Golgi apparatus, inhibits the O-GlcNAcylation of ?-catenin, and promotes competitive phosphorylation of ?-catenin, thereby preventing its translocation to the nucleus and ultimately inhibiting the invasion and metastasis of ovarian cancer. In summary, this study reveals that FZ disrupts the Golgi apparatus and inhibits the O-GlcNAcylation and nuclear translocation of ?-catenin, thereby preventing the invasion and metastasis of ovarian cancer.
  • ||||||||||  HRS-5965 / Jiangsu Hengrui Pharma
    Enrollment closed:  Efficacy and Safety of HRS-5965 in Patients With PNH Who Are Still Anemia After Anti-C5 Antibody Treatment (clinicaltrials.gov) -  Sep 12, 2025   
    P3,  N=39, Active, not recruiting, 
    In summary, this study reveals that FZ disrupts the Golgi apparatus and inhibits the O-GlcNAcylation and nuclear translocation of ?-catenin, thereby preventing the invasion and metastasis of ovarian cancer. Recruiting --> Active, not recruiting
  • ||||||||||  tecotabart vedotin (LM-302) / Sino Biopharm
    Trial completion date, Trial primary completion date:  A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study (clinicaltrials.gov) -  Sep 12, 2025   
    P2,  N=276, Recruiting, 
    Recruiting --> Active, not recruiting Trial completion date: Jan 2026 --> Jul 2028 | Trial primary completion date: Jul 2025 --> Jul 2026
  • ||||||||||  AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
    Enrollment open, Real-world evidence:  Dalpiciclib in HR+/HER2- ABC (clinicaltrials.gov) -  Sep 11, 2025   
    P=N/A,  N=103, Recruiting, 
    Trial primary completion date: Aug 2026 --> Nov 2026 Not yet recruiting --> Recruiting
  • ||||||||||  Hengqu (hetrombopag) / Jiangsu Hengrui Pharma, danazol oral / Generic mfg., cyclosporine / Generic mfg.
    Journal:  Rapid early remission in a patient with severe aplastic anemia: a case report of hetrombopag, cyclosporine, and danazol combination therapy. (Pubmed Central) -  Sep 10, 2025   
    Hematologic assessments using the NIH criteria revealed a partial response at 3 months and a complete response at 6 months, with reduced proportions of active T-cell subclones and no severe adverse events. This case suggests that the combination of CSA, HPAG, and danazol is effective in treating SAA, and a large-scale clinical trial is warranted to further confirm these promising results.
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group, famitinib (SHR 1020) / Jiangsu Hengrui Pharma
    Trial completion date:  Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer (clinicaltrials.gov) -  Sep 9, 2025   
    P3,  N=443, Active, not recruiting, 
    While these findings suggest potential advantages for certain patient populations, the retrospective design and ASA classification imbalance limit definitive conclusions, warranting prospective validation studies. Trial completion date: Apr 2025 --> May 2027
  • ||||||||||  rivocibart (SHR-1918) / Jiangsu Hengrui Pharma
    Trial completion, Enrollment change:  Evaluate the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia (clinicaltrials.gov) -  Sep 5, 2025   
    P2,  N=26, Completed, 
    This case highlights the possibility of gastric metastasis when gastrointestinal symptoms occur in patients with a history of breast cancer. Not yet recruiting --> Completed | N=20 --> 26
  • ||||||||||  Journal, PD(L)-1 Biomarker, IO biomarker:  Combined neoadjuvant chemotherapy and immunotherapy in a hepatitis B virus-positive patient with locally advanced rectal adenocarcinoma: a case report and literature review. (Pubmed Central) -  Sep 5, 2025   
    Following five cycles of cmFOLFOXIRI and two cycles of camrelizumab, significant tumor regression was achieved, with further response observed after long-course radiotherapy combined with irinotecan and capecitabine...This case underscores the potential of integrating immunotherapy into multimodal neoadjuvant regimens for MSS rectal cancer while highlighting the critical importance of HBV management to minimize reactivation risks during treatment. These findings offer valuable insights into the safe and effective use of ICIs in HBV-positive cancer patients, warranting further investigation in larger clinical studies.